Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A repeated oral dose study in healthy Japanese male subjects and a multi-center, placebo-controlled, randomized, double-blinded, parallel-group comparative study in Japanese osteoarthritis patients

Next Previous
Trial Profile

A repeated oral dose study in healthy Japanese male subjects and a multi-center, placebo-controlled, randomized, double-blinded, parallel-group comparative study in Japanese osteoarthritis patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ONO 4474 (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Ono Pharmaceutical

Most Recent Events

  • 08 Jul 2019 Efficacy, safety and tolerability results (n=110) were published in the Journal of Clinical Pharmacology.
  • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
  • 05 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top